Waltham, Mass. — Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company’s president and CEO, will present an overview of upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies, at the
following conferences:

R.W. Baird 2010 Healthcare Conference
New York, NY
Wednesday, September 15, 2010
8:30 AM EST

BioPharm America 2010
Boston, MA
Friday, September 17, 2010
10:30 AM EST

The presentations will be available at Syndax’s website, www.syndax.com.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. For more information please visit www.syndax.com.

Contact Information

Joanna Horobin, M.D.
Syndax Pharmaceuticals, Inc
Tel: 781-419-1402
jhorobin@syndax.com

Danielle Bertrand
WCG
Tel: 415-946-1056
dbertrand@wcgworld.com